ZP
CCCC icon

Zimmer Partners’s C4 Therapeutics CCCC Stock Holding History

Zimmer Partners’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-20,000
Closed -$740K – 180
2021
Q1 		$740K Hold
20,000
– – 0.01% 147
2020
Q4 		$663K Buy
+20,000
New +$580K 0.01% 114

Other funds holding CCCC

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Zimmer Partners's CCCC Position: Q2 2021 in Review

Zimmer Partners sold out of C4 Therapeutics (CCCC) in Q2 2021, closing a stake of 20,000 shares — an estimated $740K sold.

Zimmer Partners first reported a position in CCCC in Q4 2020 and held it in 2 quarters. The position peaked at $740K in Q1 2021. 107 funds tracked by Wall St. Rank hold CCCC as of Q2 2021.

  • Zimmer Partners reported no remaining C4 Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Zimmer Partners sold 20,000 C4 Therapeutics shares in Q2 2021, an estimated $740K.
  • Zimmer Partners first reported a position in C4 Therapeutics in Q4 2020 and held it in 2 quarters.
  • Zimmer Partners's C4 Therapeutics position peaked at $740K in Q1 2021.
  • 107 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2021.

Based on Zimmer Partners's 13F filing for Q2 2021, filed 16 Aug 2021.